Frédéric Desdouits

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinsons Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.

ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus on developing optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. We are also leading R&D projects aiming at developing new drugs for pediatric orphan or ultra-rare indications. ORPHELIA’s portfolio encompasses drugs for the treatment of West Syndrome (epilepsy), relapsed or refractory high-risk neuroblastoma and acute lymphoblastic leukemia, with a first marketing authorization expected in 2018. ORPHELIA is headquartered in Paris with a secondary site in Lyon area. Key investors include initiative Octalfa (lead investor) and Pierre Fabre Medicament.

Le groupe Eurobio Scientific est un acteur intégré français du diagnostic in vitro. Aujourd’hui, leader sur le marché français du diagnostic in-vitro, le groupe Eurobio Scientific poursuit son développement en intervenant de la recherche à la commercialisation de produits diagnostiques de spécialités et de produits dans le domaine des sciences de la vie. Le savoir-faire d’Eurobio Scientific repose sur la commercialisation de tests de diagnostic de spécialité auprès des laboratoires d’analyses de biologie médicale hospitaliers et privés. Le groupe est également reconnu en France comme étant le leader du marché des tests HLA pour la transplantation. Eurobio Scientific commercialise également en exclusivité des tests et des solutions automatisées conçus par nos partenaires industriels étrangers (américains, coréens, européens…) dans les domaines des maladies infectieuses, de l’auto-immunité et des contrôles qualité. Une offre de qualité : - Une gamme de réactifs et d’instruments dédiés aux laboratoires des sciences de la vie. - Fabrication de ses produits propriétaires en interne, dans l’unité de production implantée dans les locaux de son siège, dans une salle blanche de plus de 400 m² permettant la fabrication d’unité stérile. Production de qualité, appréciée des clients d’Eurobio. Un portefeuille étendu et diversifié de produits propriétaires dans quatre spécialités : la transplantation, les maladies infectieuses, les sciences du vivant et le cancer.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinsons Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.

SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1.4 MM€ and operates 24 manufacturing plants and 10 R&D centers in Europe, North America and Asia. 3,400 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers. SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.

Laboratoires Pierre Fabre held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : 💊 A pharmaceutical group with a strong positioning : medical and natural 🥈 The second largest dermo-cosmetics laboratory in the world 🥈 The second largest private French pharmaceutical group 🥇 The market leader in France for products sold over the counter in pharmacies. Our portfolio includes several medical franchises and international brands including ; Pharmaceutical Care Pierre Fabre Oncologie Pierre Fabre Dermatologie Naturactive Eau Thermale Avène Klorane Ducray René Furterer A-Derma Pierre Fabre Oral Care Glytone (US) Darrow (Brasil) Established in the Occitanie region since its creation, we manufacture over 95% of our products in France. We keep innovating passionately with our teams in 2 innovation centers in Brasil and Japan as well as in 6 R&D centers in France. Thanks to our 9,600 employees in 44 subsidiaries and our distribution activities in 120 countries, our group generated €2.7 billion in revenues in 2022, 69% of which is from international business. Pierre Fabre Group has a unique company structure. 86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan. In 2020, the independent organization ECOCERT Environment awarded Pierre Fabres CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard.

ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus on developing optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. We are also leading R&D projects aiming at developing new drugs for pediatric orphan or ultra-rare indications. ORPHELIA’s portfolio encompasses drugs for the treatment of West Syndrome (epilepsy), relapsed or refractory high-risk neuroblastoma and acute lymphoblastic leukemia, with a first marketing authorization expected in 2018. ORPHELIA is headquartered in Paris with a secondary site in Lyon area. Key investors include initiative Octalfa (lead investor) and Pierre Fabre Medicament.